Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough?

Structure Therapeutics Inc. has evolved from a “dark horse” to a leading contender in the oral GLP-1 obesity drug market. GPCR's market cap surged from $1.3B to $5B in five months, reflecting heightened investor confidence after a successful Phase II readout and improved competitive positioning. The weight-loss drug market has shifted to mass-market pricing, with cash options as low as $149/month, broadening patient access.

Seeking Alpha • Feb 18, 2026

This Healthcare Company Believes Its GLP-1 Pill Could Be "Next in Line" After Novo Nordisk and Eli Lilly. Its Valuation Is a Fraction of Theirs.

Structure Therapeutics' GLP-1 drug candidate, aleniglipron, has helped people lose up to 15% of their body weight. Its share price has tripled in the past year, suggesting investors have already priced approval into its valuation.

The Motley Fool • Feb 5, 2026

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the blockbuster weight-loss market.

Reuters • Feb 3, 2026

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Structure Therapeutics CEO Ray Stevens talked about the biotech's path forward and his expectations for the future of the booming GLP-1 space.

CNBC • Jan 21, 2026

Structure CEO Ray Stevens talks its obesity drug portfolio

Ray Stevens, Structure CEO, joins 'Fast Money' to talk its weigh-loss drug pipeline, potential M&A, and more.

CNBC Television • Jan 15, 2026

A 10% Owner Of Structure Therapeutics Shed Shares

In early December, over 50,000 shares of Structure Therapeutics were indirectly sold by a stakeholding company, valued at nearly $4 million. The stakeholding company is predominantly controlled by the Johnson family, who are highly active in the pharmaceutical sector.

The Motley Fool • Jan 13, 2026

Can This Stock Double Again in 2026?

Structure Therapeutics' positive phase 2 data for aleniglipron sent its stock price soaring last year. The medicine could join the fast-growing weight loss market, but it will face plenty of competition.

The Motley Fool • Jan 11, 2026

What Awaits These 4 Biotech Stocks That More Than Doubled in 2025

IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.

Zacks Investment Research • Dec 22, 2025

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the closing of its previously announced upsized underwritten public offering of 9,961,538 American depositary shares (ADSs), each representing three ordinary shares, which includes the full exercise of the underwriters' option to purchase up to 1,500,000 additional ADSs at a price to the public of $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at a price to the public of $64.9999 per pre-funded warrant. All of the securities in the offering were sold by Structure Therapeutics.

GlobeNewsWire • Dec 11, 2025

In The 'Uber Bull' Biotech Market, Is Structure The Next Metsera?

In a post-Metsera world, Structure Therapeutics could be the next big takeover candidate, analysts said Tuesday.

Investors Business Daily • Dec 9, 2025